Nakamura Harumasa, Uyama Yoshiaki
Institute of Genetic Medicine, Newcastle University, Newcastle, UK.
Brain Nerve. 2012 Mar;64(3):229-35.
Neurological disorders have varying prevalence rates and cause short- and long-term impairments and disabilities. These disorders involve high costs and impose burdens on patients, caregivers, and society. Therefore, continued research and new therapeutic development in these areas have been expected worldwide. Recently, much attention has been paid to neurological drug development, and pharmaceutical companies are conducting many clinical trials in neurological fields. Industry-sponsored clinical trials have been performed not only in North America and western Europe but also in the so-called emerging regions such as the eastern European, Latin American, and Asian countries in recent years. In Japan, although the number of global clinical trials has increased in recent years, there is still a large gap between Japan and the US or European countries with regard to access to neurological drugs. In this article, we have summarized the status of new drug development for neurological disorders and the delays in neurological drug development in Japan. We have also discussed future tasks, including those for academia, related to promoting clinical trials in neurological fields in Japan.
神经系统疾病的患病率各不相同，会导致短期和长期的损伤及残疾。这些疾病成本高昂，给患者、护理人员和社会带来负担。因此，全球都期望在这些领域持续开展研究并开发新的治疗方法。最近，神经系统药物研发受到了广泛关注，制药公司正在神经领域开展许多临床试验。近年来，不仅在北美和西欧，而且在东欧、拉丁美洲和亚洲国家等所谓的新兴地区都开展了行业赞助的临床试验。在日本，尽管近年来全球临床试验的数量有所增加，但在获得神经系统药物方面，日本与美国或欧洲国家之间仍存在很大差距。在本文中，我们总结了神经系统疾病新药研发的现状以及日本神经系统药物研发的延迟情况。我们还讨论了未来的任务，包括学术界在推动日本神经领域临床试验方面的任务。
